ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

SAGE Sage Therapeutics Inc

13,71
0,605 (4,62%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Sage Therapeutics Inc SAGE NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,605 4,62% 13,71 06:00:08
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
13,46 13,45 13,97 13,94 13,105
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202412:30BWSage Therapeutics Announces First Quarter 2024 Financial..
17.4.202412:30BWSage Therapeutics Announces Topline Results from Phase 2..
11.4.202412:30BWSage Therapeutics to Report First Quarter 2024 Financial..
28.2.202412:30BWSage Therapeutics to Present at Upcoming March Investor..
21.2.202422:35EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
15.2.202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202422:09EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
14.2.202413:49EDGAR2Form S-8 - Securities to be offered to employees in employee..
14.2.202413:20EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
14.2.202412:45EDGAR2Form 8-K - Current report
14.2.202412:30BWSage Therapeutics Announces Fourth Quarter and Full Year..
31.1.202423:25EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
31.1.202422:50EDGAR2Form 8-K - Current report
31.1.202412:30BWSage Therapeutics to Report Fourth Quarter and Full Year..
24.1.202422:10EDGAR2Form 8-K - Current report
23.1.202414:13EDGAR2Form SC TO-I - Tender offer statement by Issuer
08.1.202412:45EDGAR2Form 8-K - Current report
08.1.202412:32BWSage Therapeutics to Provide Business Updates at 42nd Annual..
08.1.202412:30BWSage Therapeutics Announces Changes to Board of Directors
04.1.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.1.202412:30BWSage Therapeutics to Present at the 42nd Annual J.P. Morgan..
19.12.202314:32EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
19.12.202314:30EDGAR2Form DEF 14A - Other definitive proxy statements
14.12.202312:30BWZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for..
08.12.202315:00EDGAR2Form SC TO-C - Written communication relating to an issuer..
08.12.202314:30EDGAR2Form PRE 14A - Other preliminary proxy statements
08.11.202312:30BWSage Therapeutics to Present at Upcoming November Investor..
07.11.202313:39EDGAR2Form 8-K - Current report
07.11.202313:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07.11.202313:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202312:46EDGAR2Form 8-K - Current report
07.11.202312:30BWSage Therapeutics Announces Third Quarter 2023 Financial..
24.10.202312:30BWSage Therapeutics to Report Third Quarter 2023 Financial..
18.10.202313:10DJNSage Therapeutics Gets FDA Orphan Designation for SAGE-718..
18.10.202312:30BWSage Therapeutics Announces U.S. Food and Drug..
06.9.202312:30BWSage Therapeutics to Present at Upcoming September Investor..
31.8.202312:45EDGAR2Form 8-K - Current report
31.8.202312:30BWSage Therapeutics Implements Strategic Reorganization to..
11.8.202314:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.8.202313:51IHMARKETNEWSTuesday’s Wall Street Highlights: Novo Nordisk, RingCentral,..
07.8.202314:18DJNSage Therapeutics Shares Slide Premarket After Zurzuvae MDD..
07.8.202313:49EDGAR2Form S-8 - Securities to be offered to employees in employee..
07.8.202313:26IHMARKETNEWSMonday’s Wall Street Highlights: Berkshire Hathaway, Tesla,..
07.8.202313:23DJNSage Therapeutics Mulls Job, Pipeline Cuts After FDA..
07.8.202312:45EDGAR2Form 8-K - Current report
07.8.202312:30BWSage Therapeutics Announces Second Quarter 2023 Financial..
05.8.202304:45BWSage Therapeutics to Host Business Update Webcast and..
05.8.202304:42BWFDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral..
05.6.202312:30BWSage Therapeutics to Present at the Goldman Sachs 44th..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock